Fosamprenavir plus Ritonavir Increases Plasma Ketoconazole and Ritonavir Exposure, while Amprenavir Exposure Remains Unchanged

Lignende værker

• Ritonavir Increases Plasma Amprenavir (APV) Exposure to a Similar Extent when Coadministered with either Fosamprenavir or APV
  af: Wire, Mary B., et al.
  Udgivet: (2006)
• Pharmacokinetic Interaction between Fosamprenavir-Ritonavir and Rifabutin in Healthy Subjects
  af: Ford, Susan L., et al.
  Udgivet: (2008)
• Pharmacokinetic and Safety Evaluation of High-Dose Combinations of Fosamprenavir and Ritonavir
  af: Shelton, Mark J., et al.
  Udgivet: (2006)
• Pharmacokinetics of Fosamprenavir plus Ritonavir in Human Immunodeficiency Virus Type 1-Infected Adult Subjects with Hepatic Impairment
  af: Pérez-Elías, María J., et al.
  Udgivet: (2009)
• Plasma Amprenavir Pharmacokinetics and Tolerability following Administration of 1,400 Milligrams of Fosamprenavir Once Daily in Combination with either 100 or 200 Milligrams of Ritonavir in Healthy Volunteers
  af: Ruane, Peter J., et al.
  Udgivet: (2007)